Neurotechnology SIG Webinar Series: Dementia Biodesign
According to Alzheimer’s UK, 850,000 people in the UK and up to 50 million people worldwide have dementia and with an ageing society, these numbers are going to increase. Dementia can have enormous effects, not only to those suffering but also family members and others caring for them, but there are currently no effective therapies available.
However, just as the number of people suffering from neurological diseases is on the rise, many pharmaceutical companies are pulling back from dementia research due to disappointing results.
Neurotechnology offers a new way of treating dementia. New technologies are being developed which could have an enormous impact on the treatment and even prevention of dementia. There is growing evidence that technologies such as deep brain stimulation and transcranial magnetic stimulation could help treat some of the effects of dementia and brain-computer interfaces are now able to detect the first signs of dementia years before symptoms appear.
The KTN’s Neurotechnology Special Interest Group is holding the fourth in its series of biodesign workshops in collaboration with the UK Dementia Research Institute where we will explore novel neurotechnologies to treat dementia, discuss barriers to adoption and new opportunities in the field. The workshop aims to bring together clinicians, companies, academics, charities and other stakeholders, to accelerate the development of new neurotechnologies for dementia.
About the Neurotechnology Special Interest Group
The UK already has a world leading research base in neurotechnology. The Neurotechnology Special Interest Group will help transfer knowledge from academia to the fast-growing industry sector and will provide a vital meeting place between clinicians and technologists. The aims of the SIG are to grow the neurotechnology community and accelerate innovation through cross-sector collaborations.
Follow the link below to find out more about this event and to register.